mgmiR Diagnostic Panel for HNSCC Early Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting head and neck squamous cell carcinoma (HNSCC) are inadequate, leading to poor prognosis due to late-stage diagnosis, and there is a need for early detection tools that can utilize non-invasive samples like saliva and blood.
Innovation Solution
A diagnostic panel of methylated genomic loci encoding microRNA (mgmiR) markers is developed, which uses quantitative MS-PCR to detect methylation levels in specific microRNA genes, demonstrating 90% sensitivity and 100% specificity for HNSCC detection, and can identify hypermethylation in adjacent mucosa.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If conventional detection methods are used for HNSCC, then the diagnosis is made at later stages, but the survival rates remain poor and stagnant
Solution Approach 1:
The patent applies preliminary action by developing a detection method that identifies HNSCC at pre-cancerous or early cancerous stages through analysis of methylation patterns in oral rinse samples. This allows intervention before the disease progresses to advanced stages, thereby improving survival outcomes. The method detects epigenetic changes that occur early in carcinogenesis, enabling timely clinical action.
2Measurement precision
If invasive biopsy methods are used for detection, then diagnostic accuracy may be improved, but patient comfort and ease of sampling deteriorates
Solution Approach 1:
The patent uses an intermediary approach by analyzing methylation patterns in oral rinse samples, which serve as a non-invasive proxy for detecting HNSCC. Instead of directly biopsying tumor tissue, the method detects epigenetic changes in shed oral cells that contain information about the presence of malignancy. This intermediary sampling method maintains diagnostic accuracy while eliminating the invasiveness of traditional biopsy procedures.
3Device complexity
If traditional detection methods are used, then existing diagnostic tools are simple to implement, but they cannot detect HNSCC at early stages with high sensitivity
Solution Approach 1:
The patent applies parameter changes by shifting the diagnostic parameter from detecting gross morphological changes or protein markers to detecting epigenetic methylation patterns at the DNA level. This parameter change enables detection of subtle early molecular changes that precede visible tumor formation. The method uses quantitative analysis of methylation status at specific genomic loci to achieve high sensitivity while maintaining a relatively simple workflow through oral rinse collection and PCR-based detection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mgmiR panel effectively detects HNSCC with high sensitivity and specificity, and its ability to analyze saliva and blood samples makes it a promising tool for early detection and potentially pre-cancerous changes.
Implementation Method 1
measuring methylation level of at least one genomic locus encoding at least one microRNA
Implementation Method 2
quantitative MS-PCR to detect methylation levels in specific microRNA genes
Data Source
AI summary
Disclosed is a diagnostic panel of methylated genomic loci encoding microRNA (mgmiR) markers that demonstrated 90% sensitivity and 100% specificity in the detection of head and neck squamous cell carcinoma (HNSCC). These results represent the first use of quantitative MS-PCR for the detection of mgmiRs. In addition, this panel demonstrates the ability to detect hypermethylation in the adjacent mucosa of cancer patients, suggesting its utility in early detection. This panel is also capable of detecting cancer by using saliva, blood and FNA tissue samples.